The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...

Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate ...

In patent damages calculations, an expert generally faces the task of comparing the actual outcome (with infringement) to the ...

HYDERABAD -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for a double-digit share in its core U.S. market for its new launches ...

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars launching next fiscal year. The U.S. market, already ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar.

A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while ...

Tocilizumab-anoh is the seventh biosimilar by Celltrion to receive FDA approval, enhancing their treatment portfolio. Avtozma, the third biosimilar to Actemra, has received FDA approval for ...

On January 29, 2025, the Federal Circuit issued paired decisions addressing Samsung Bioepis’s (“SB”) and Formycon AG’s (“Formycon”) appeals ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth ...